Moreover, the widespread use of mammographic screening, improved understanding of the nature and biology of BC, and the increasing array of systemic therapy options (hormone, chemotherapy, anti‐HER2, and other targeted therapy and immunotherapy)35 further emphasizes the need to utilize molecular prognostic and predictive markers. This evidence concerns the gene ERBB2 and breast cancer.